ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic OutlookGlobeNewsWire • 01/09/20
ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate FractionsGlobeNewsWire • 01/07/20
ADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics AssociationGlobeNewsWire • 11/04/19
ADMA Biologics Adds ASCENIV's First Sale To A Strong List Of 2019 AccomplishmentsSeeking Alpha • 10/24/19
ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal ImmunotherapyGlobeNewsWire • 10/17/19
ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®GlobeNewsWire • 08/22/19
ADMA Biologics: Significant Derisking, Product Launches In Second Half Of The YearSeeking Alpha • 05/28/19
The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis EarningsBenzinga • 04/03/19
ADMA Biologics' stock rockets on heavy volume after FDA approval of immunodeficiency treatmentMarket Watch • 04/02/19